Search - tctmd.com

Displaying 21 - 40 of 5391

Sort: Relevancy | Date

News Daily News

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

Yael L. Maxwell

March 16, 2026

News Conference News CRT 2026

CARPOOL Radial Access as Good as Femoral in PAD Procedures

L.A. McKeown

March 16, 2026

News Conference News CRT 2026

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

L.A. McKeown

March 16, 2026

News Daily News

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Michael O'Riordan

March 13, 2026

News Daily News

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

Yael L. Maxwell

March 12, 2026

News Conference News THT 2026

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

Todd Neale

March 10, 2026

News Daily News

Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI

Caitlin E. Cox

March 10, 2026

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

L.A. McKeown

March 09, 2026

News Daily News

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

L.A. McKeown

March 06, 2026

News Conference News THT 2026

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

Todd Neale

March 04, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Presentation THT 2026

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Presenter: JoAnn Lindenfeld

March 04, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Advertisement

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

CARPOOL Radial Access as Good as Femoral in PAD Procedures

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

CRT 2026: What to Expect in Washington, DC

How Will Guideline Committees View Results From RWE Trials?

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content